In a patient with a recent 3 mm subdural hematoma after a fall, seizures, and intubation, who has a coronary stent and has been on prasugrel 10 mg daily, is it appropriate to restart prasugrel now at 5 mg?

No, it is not appropriate to restart prasugrel 5 mg now

Given this patient's recent 3 mm subdural hematoma (SDH) from a fall with seizures requiring intubation, restarting prasugrel at this time—even at the reduced 5 mg dose—carries unacceptable bleeding risk that outweighs the thrombotic risk from the coronary stent.

Key Clinical Considerations

Timing and Bleeding Risk

The discharge recommendation to "consider restarting prasugrel in 2 weeks if clinically indicated" provides critical guidance. This patient is currently well within that 2-week window where intracranial bleeding risk remains elevated. Prasugrel is contraindicated in patients with active pathological bleeding 1, 2, 1, 3, and a recent SDH—particularly one associated with trauma, seizures, and requiring intubation—represents an ongoing bleeding risk.

The FDA label explicitly states that prasugrel increases bleeding risk, with the highest risk occurring initially after starting therapy 3. In patients with propensity to bleed (including recent trauma), prasugrel carries additional risk 1, 2, 1, 3.

Subdural Hematoma-Specific Risks

Research demonstrates that dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin increases subdural hematoma risk 2-fold compared to aspirin alone (risk ratio 2.0,95% CI 1.0-3.8) 4. While this data is for clopidogrel, prasugrel is a more potent P2Y12 inhibitor with greater bleeding risk than clopidogrel 5, 6, 1.

The combination of alcohol use disorder, seizure history, fall risk, and recent intracranial hemorrhage creates a particularly high-risk bleeding profile that guidelines specifically identify as requiring careful consideration before antiplatelet therapy 1, 2, 1, 3.

Stent Thrombosis Risk Assessment

Timeline Considerations

The critical question is: when was the stent placed? The documentation states "stent placed in [DATE]" but the year is unclear. This is essential because:

• If the stent is >12 months old: The patient has already completed the minimum recommended DAPT duration 7, 8. Continuing prasugrel beyond 12 months is only a conditional recommendation (Class IIb) for patients at low bleeding risk 8—which this patient clearly is not.

• If the stent is <12 months old but >3 months old: There is still elevated stent thrombosis risk, but guidelines acknowledge that in patients who develop high bleeding risk, discontinuation after 6 months "may be reasonable" (Class IIb) 8.

• If the stent is <3 months old: This represents the highest thrombotic risk period, but even here, active bleeding or high bleeding risk may necessitate stopping DAPT 9, 8.

Type of Stent Matters

The documentation is unclear whether a stent was placed during the PDA occlusion event. If no stent was placed, or if a bare metal stent (BMS) was used, the minimum DAPT duration is shorter (1 month for BMS) 7, 2, 1.

Recommended Management Algorithm

Immediate Actions (Now)

1. Do not restart prasugrel at this time
2. Continue aspirin monotherapy if not contraindicated (aspirin alone has lower bleeding risk than DAPT)
3. Obtain repeat head CT to assess SDH stability
4. Clarify exact stent placement date and type from medical records

At 2-Week Mark (As Per Discharge Recommendation)

Repeat head CT is mandatory before considering prasugrel restart. Then assess:

• If SDH has resolved or is stable AND no new neurological symptoms: Consider restarting prasugrel 5 mg (appropriate dose given likely age ≥75 years or weight <60 kg based on alcohol use disorder) 1, 2, 1, 10

• If SDH has enlarged or new symptoms present: Continue aspirin monotherapy only; consider cardiology consultation regarding alternative strategies (e.g., shorter DAPT duration, aspirin alone)

• If stent is >12 months old: Strong consideration for aspirin monotherapy indefinitely given bleeding history 8

Ongoing Risk Mitigation

This patient has multiple ongoing bleeding risk factors that will persist:

• Alcohol use disorder (increases fall risk and may affect medication compliance)
• Seizure disorder (increases fall/trauma risk)
• History of intracranial hemorrhage

Even after restarting prasugrel, this patient requires:

• Close neurological monitoring
• Seizure control optimization
• Fall prevention strategies
• Alcohol cessation counseling
• Consider lower aspirin dose (75-81 mg) if on DAPT 10, 8

Critical Pitfalls to Avoid

1. Do not assume the 5 mg dose is "safe enough": While 5 mg prasugrel has lower bleeding risk than 10 mg, it still significantly increases bleeding compared to aspirin alone 1, 2, 1, 5

2. Do not restart without imaging: The 2-week recommendation assumes clinical reassessment including repeat imaging to ensure SDH stability

3. Do not ignore the seizure history: Seizures increase fall risk, which increases risk of recurrent intracranial hemorrhage on antiplatelet therapy 11

4. Do not forget prasugrel is contraindicated if stroke/TIA occurs: If any new neurological events occur, prasugrel becomes absolutely contraindicated 1, 2, 1, 3

The Bottom Line

Wait the full 2 weeks as recommended, obtain repeat head CT, and only then consider restarting prasugrel 5 mg if imaging shows stability and no new neurological symptoms have occurred. The discharge team's recommendation to wait 2 weeks was appropriate and should be followed. Starting now, before that window, prioritizes thrombotic risk over a very real and recent bleeding complication—the wrong priority in this clinical context.